Anhui Anke Biotechnology (Group) Company., Limited operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Anhui Anke Biotechnology (Group) Company., Limited with three other companies in this sector in China: Shanghai Kaibao Pharmaceutical Company Limited (2018 sales of 1.50 billion Chinese Renmimbi [US$213.20 million] of which 100% was Industrial), Yipinhong Pharmaceutical Co Ltd (1.43 billion Chinese Renmimbi [US$203.10 million] of which 67% was Pharmaceutical Manufacturing), and Beijing Science Sun Pharmaceutical Co Ltd (1.43 billion Chinese Renmimbi [US$202.84 million] of which 54% was Immune system medication).

Sales Analysis. During the year ended December of 2018, sales at Anhui Anke Biotechnology (Group) Company., Limited were 1.46 billion Chinese Renmimbi (US$207.64 million). This is an increase of 33.3% versus 2017, when the company's sales were 1.10 billion Chinese Renmimbi. This was the fifth consecutive year of sales increases at Anhui Anke Biotechnology (Group) Company., Limited (and since 2013, sales have increased a total of 240%). Sales of Medicine saw an increase that was more than double the company's growth rate: sales were up 101.6% in 2018, from 217.54 million Chinese Renmimbi to 438.64 million Chinese Renmimbi. Not all segments of Anhui Anke Biotechnology (Group) Company., Limited experienced an increase in sales in 2018: sales of Raw Material Medicine fell 18.4% to 68.01 million Chinese Renmimbi.